share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：諾和諾德-股票回購計劃
美股SEC公告 ·  09/09 23:10
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated this program on August 7, 2024, as part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024. From August 26 to August 30, 2024, Novo Nordisk repurchased a total of 204,000 B shares at an average price of DKK 910.88, amounting to a transaction value of DKK 185,845,531. This brings the accumulated repurchases under the program to 744,187 B shares for a total cost of DKK 671,844,599. As of August 30, the company owns 13,139,944 B shares as treasury shares, which is 0.3% of the share capital. The total number of A and B shares, including treasury shares, is 4,465,000,000. Since the beginning of the repurchase plan on February 6, 2024, Novo Nordisk has bought back 11,811,313 B shares at an average price of DKK 880.47 per share, totaling DKK 10,399,550,649. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated this program on August 7, 2024, as part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024. From August 26 to August 30, 2024, Novo Nordisk repurchased a total of 204,000 B shares at an average price of DKK 910.88, amounting to a transaction value of DKK 185,845,531. This brings the accumulated repurchases under the program to 744,187 B shares for a total cost of DKK 671,844,599. As of August 30, the company owns 13,139,944 B shares as treasury shares, which is 0.3% of the share capital. The total number of A and B shares, including treasury shares, is 4,465,000,000. Since the beginning of the repurchase plan on February 6, 2024, Novo Nordisk has bought back 11,811,313 B shares at an average price of DKK 880.47 per share, totaling DKK 10,399,550,649. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
諾和諾德(Novo Nordisk A/S)是一家領先的全球醫療保健公司，報告了其回購計劃的進展。這家總部位於丹麥的公司於2024年8月7日啓動了這個計劃，作爲一個更大的200億丹麥克朗的回購計劃的一部分，該計劃將在2024年2月6日開始的12個月期間內進行。2024年8月26日至8月30日，諾和諾德以平均價格910.88丹麥克朗回購了2040000億股份，交易價值達到185,845,531丹麥克朗。這使得該計劃的累計回購數量達到了7441870億股，總成本爲671,844,599丹麥克朗。截至2024年8月30日，該公司擁有131399440億股作爲庫藏股，佔有0.3%的股本。包括庫藏股在內...展開全部
諾和諾德(Novo Nordisk A/S)是一家領先的全球醫療保健公司，報告了其回購計劃的進展。這家總部位於丹麥的公司於2024年8月7日啓動了這個計劃，作爲一個更大的200億丹麥克朗的回購計劃的一部分，該計劃將在2024年2月6日開始的12個月期間內進行。2024年8月26日至8月30日，諾和諾德以平均價格910.88丹麥克朗回購了2040000億股份，交易價值達到185,845,531丹麥克朗。這使得該計劃的累計回購數量達到了7441870億股，總成本爲671,844,599丹麥克朗。截至2024年8月30日，該公司擁有131399440億股作爲庫藏股，佔有0.3%的股本。包括庫藏股在內的A股和B股的總股數爲4,465,000,000。自2024年2月6日回購計劃開始以來，諾和諾德已以平均價格880.47丹麥克朗回購了118113130億股份，總計10,399,550,649丹麥克朗。諾和諾德的股票在納斯達克哥本哈根交易所上市，其美國存託憑證(ADRs)在紐約證券交易所上市。

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。